Go Pro
OTCMKTS:BTCA

Bactolac Pharmaceutical (BTCA) Stock Price, News & Analysis

Bactolac Pharmaceutical logo
$120,000.00 0.00 (0.00%)
As of 09/18/2017

About Bactolac Pharmaceutical Stock (OTCMKTS:BTCA)

Key Stats

Today's Range
$120,000.00
$120,000.00
50-Day Range
$120,000.00
$120,000.00
52-Week Range
$120,000.00
$120,000.00
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bactolac Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of topical drug products. The company’s offerings span both prescription and over-the-counter categories, emphasizing aseptically compounded formulations for skin care, wound management and infection control. Bactolac’s manufacturing facilities are designed and operated under current Good Manufacturing Practices (cGMP) regulations, supporting both its in-house brands and contract manufacturing partnerships.

The company’s product portfolio includes topical antiseptics, first-aid antibiotic ointments, acne treatments and specialty dermatological preparations. Through proprietary manufacturing processes, Bactolac supplies municipally branded and private-label formulations to hospitals, nursing homes, pharmacies and retail channels. In addition to end-product manufacturing, the company offers development services for custom topical formulations, including analytical testing, stability studies and regulatory support for clients seeking to bring new products to market.

Founded in 1979 and headquartered in West Bridgewater, Massachusetts, Bactolac Pharmaceutical serves customers across North America and has relationships in select international markets. The company’s management team brings experience in pharmaceutical operations, quality assurance and regulatory affairs, guiding strategic investments in manufacturing capabilities and product development. With over four decades of topical formulation expertise, Bactolac continues to pursue growth through expanded contract manufacturing services and targeted product innovation.

AI Generated. May Contain Errors.

Receive BTCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bactolac Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BTCA Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

BTCA Stock Analysis - Frequently Asked Questions

Bactolac Pharmaceutical's stock was trading at $120,000.00 at the start of the year. Since then, BTCA shares have increased by 0.0% and is now trading at $120,000.00.

Shares of BTCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bactolac Pharmaceutical investors own include Grayscale Bitcoin Mini Trust ETF (BTC), Ford Motor (F), Meta Platforms (META), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO) and

Company Calendar

Today
8/17/2026
Fiscal Year End
9/30/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drugs, Proprietaries, & Sundries
Sub-Industry
N/A
Current Symbol
OTCMKTS:BTCA
CIK
N/A
Fax
N/A
Employees
126
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.01
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (OTCMKTS:BTCA) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners